USA - NASDAQ:MDXH - BE0974461940 - Common Stock
ChartMill assigns a Buy % Consensus number of 87% to MDXH. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-07 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-10-31 | Lake Street | Initiate | Buy |
| 2024-03-07 | BTIG | Maintains | Buy -> Buy |
| 2024-03-07 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-11-09 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-05-31 | TD Cowen | Initiate | Outperform |
| 2023-05-16 | BTIG | Maintains | Buy -> Buy |
| 2023-03-24 | William Blair | Initiate | Outperform |
| 2023-03-06 | Piper Sandler | Maintains | Overweight |
| 2022-08-26 | BTIG | Maintains | Buy |
| 2021-11-29 | BTIG | Initiate | Buy |
| 2021-11-29 | Oppenheimer | Initiate | Outperform |
| 2021-11-29 | Piper Sandler | Initiate | Overweight |
12 analysts have analysed MDXH and the average price target is 6.63 USD. This implies a price increase of 60.92% is expected in the next year compared to the current price of 4.12.
The consensus rating for MDXHEALTH (MDXH) is 86.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering MDXHEALTH (MDXH) is 12.